MSD India to sign agreement with 5 Indian drug firms for Molnupiravir
Indian subsidiary of Merck Sharp and Dohme (MSD), a drug firm has decided to enter into voluntary licensing agreements for investigational oral antiviral drug candidate ‘molnupiravir’, it said on Tuesday.
The drug is being studied for the treatment of Covid-19 with Indian firms Sun Pharma, Cipla, Dr Reddy’s, Emcure Pharma and Hetero Labs.
Molnupiravir is currently being studied in a Phase 3 trial for treatment of non-hospitalized patients with confirmed Covid-19, MSD India said in a statement.
Recent Posts
India Reports Highest Tuberculosis Cases in 2024 Amid Progress in TB Control
India has recorded its highest-ever number of tuberculosis (TB) cases in 2024, with 26.07 lakh…
Elon Musk’s 120-Hour Workweek: The Dark Reality
Elon Musk is known for his relentless work ethic and high expectations from his teams.…
Patanjali’s Renogrit: A Breakthrough in Kidney Protection During Cancer Treatment
In 2024, a significant advancement in nephroprotection emerged from Patanjali Research Institute with the development…
Sunita Williams & Butch Wilmore’s 45-Day Rehab After Space Mission
NASA astronauts Sunita Williams and Barry "Butch" Wilmore have returned to Earth after an extended…
Bacterial Meningitis: The Silent Threat You Can’t Ignore
Bacterial meningitis is a life-threatening infection that leads to inflammation of the meninges, the protective…
Rare Human Coronavirus HKU1 Detected in Kolkata
A 45-year-old woman from Kolkata has been diagnosed with human coronavirus HKU1 (HCoV-HKU1), a rare…